Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Sanofi Expands Insulin Savings Program To Cover All US Patients
01:40pm, Friday, 26'th Sep 2025
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA's (NASDAQ: S
Sanofi to offer all insulin products for $35 per month in US
08:26am, Friday, 26'th Sep 2025
French drugmaker Sanofi said on Friday it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status.
Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
08:00am, Friday, 26'th Sep 2025
MORRISTOWN, N.J. , Sept. 26, 2025 /PRNewswire/ -- Sanofi US today announces a broad expansion of its Insulins Valyou Savings Program by offering a 30-day supply of any Sanofi insulin for $35 to all pa
French court orders Sanofi to pay $177 million for anti-competitive behaviour
08:49am, Wednesday, 24'th Sep 2025
A Paris court on Wednesday ordered Sanofi and its Winthrop unit to pay 150.7 million euros ($177.1 million) in damages to France's national health insurance fund (CNAM) for anti-competitive practices
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund will remain focused on Sanofi's key areas of immunology, rare di
Press release: Availability of the Q3 2025 Aide mémoire
01:00am, Wednesday, 24'th Sep 2025
Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3 2025 Aide mémoire is available on the "Investors" page of the company's website: Thi
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
02:03pm, Tuesday, 23'rd Sep 2025
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Press Release: Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
01:00am, Tuesday, 23'rd Sep 2025
Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK ex
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
01:06pm, Monday, 22'nd Sep 2025
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing
12:31pm, Monday, 22'nd Sep 2025
The FDA extends SNY's tolebrutinib NDA review by three months, with decision now expected on Dec. 28, 2025.
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
01:00am, Monday, 22'nd Sep 2025
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three
Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
12:30am, Monday, 22'nd Sep 2025
Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent sig
Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
01:00am, Wednesday, 17'th Sep 2025
EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary e
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
01:46pm, Thursday, 11'th Sep 2025
Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.
Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
01:00am, Thursday, 11'th Sep 2025
Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate t
